theme04のラベル

In collaboration with you, we will focus on our mission of “Creating for Tomorrow” and accelerate the research and development of next-generation drugs that can contribute to the treatment of bone and cartilage diseases.

Pharmaceuticals Research Center
Laboratory for Pharmacology

theme04のメイン画像

Creating for Tomorrow


“ Bones and Cartilage ”

Message 

薬理研究部 ユニットリーダー 薬学博士 画像

Ryoko Takao, PhD

Senior Principal Scientist
Laboratory for Pharmacology

Masahiro Nishida, PhD

Senior Principal Scientist
Laboratory for Pharmacology

Asahi Kasei Pharma has developed many pharmaceutical medicines. They include the synthetic calcitonin derivative Elcitonin®, the immune disorder drug Bredinin® (for treating rheumatoid arthritis and other diseases), Reclast® and the human parathyroid hormone preparation Teribone® (for treating osteoporosis), and XIAFLEX® (for treating Dupuytren's contracture). Through the introduction of these drugs, we have long provided new treatment options in the field of orthopedics. Currently, we are focused on developing therapeutic agents with new mechanisms of action for the regeneration of bone and cartilage. We have ongoing projects that will soon be initiating clinical trials.

We are interested in applications proposing to develop novel drugs or therapeutic approaches in the field of bone and cartilage regeneration. This year, we invite proposals addressing novel technologies that can increase (i) the accuracy of non-clinical drug efficacy assessment or (ii) the efficiency of translation between in non-clinical and clinical efficacy.

Recruitment theme 

Drug Development Technologies

4.1 New drug discovery technologies which address the issues of human translation in the field of bone regenerative medicine
  1. 4.1.1 Animal models

    • Animal models for evaluating the regenerative effects of drugs used to treat refractory bone diseases, such as osteonecrosis and long bone fractures with non-union or delayed healing
  2. 4.1.2 Diagnostic modalities for drug development (e.g., biomarkers and imaging technologies for clinical and/or research uses)

    • A noninvasive or minimal invasive method to monitor a disease progression or an efficacy of treatment such as
    a )
    blood or urine biomarkers
    b )
    biomechanical evaluation
    c )
    imaging technologies or analysis methods (such as CT and MRI)

    (Ideal methods should be applicable in both nonclinical and clinical settings.)

4.2 New technologies for drug discovery that directly address clinical needs in the field of cartilage regenerative medicine
  1. 4.2.1 In vitro assay systems or animal models

    • In vitro assay systems to evaluate regenerative effects of drugs or cells on articular cartilage degeneration or intervertebral disc degeneration: Examples) Co-cultures of graft cells with isolated animal cartilage cells. Cartilage organ culture systems.
    • Animal models to evaluate regenerative effects of drugs or cells on articular cartilage degeneration (OA, TA) or intervertebral disc degeneration: Laboratory animals that can potentially be used for these models include rats, miniature pigs, rabbits, and monkeys.
      (Ideal models should allow for the long-term assessment of human cell-based treatment under immunosuppressive conditions.)
  2. 4.2.2 Diagnostic modalities for drug development (e.g., biomarkers and imaging technologies)

    • Techniques for tracking disease progression or therapeutic response in a noninvasive or minimally invasive manner:
    a )
    blood or urine biomarkers
    b )
    biomechanical measurement devices
    c )
    imaging technologies and image analysis tools (such as CT and MRI)

    (Ideal methods should be applicable in both nonclinical and clinical settings.)

Subscription 

Click “Apply” to proceed to the application form.

pagetopボタン